



ASCEPT-MPGPCR

JOINT SCIENTIFIC MEETING **27-30 NOVEMBER 2016**

MELBOURNE CONVENTION & EXHIBITION CENTRE

Therapeutic targeting: right place, right time, right effect

www.ascept-mpgpcr2016.com



Meeting Poster Program

Monday 28 December, 09:30 - 10:25 and 12:30 - 13:25

Posterboard number	Paper Title	Presenter	Paper reference	Theme
500	Combined administration of insulin and leptin significantly increased Fos production in the arcuate nucleus and renal sympathetic nerve activity	Emilio Badoer	500	Cardiovascular
501	GPR37L1: an orphan G protein-coupled receptor contributing to sex differences in blood pressure regulation	James Coleman	232	Cardiovascular
502	A small-molecule inhibitor of NLRP3 inflammasome activity, MCC950, reduces blood pressure and restores renal function in hypertensive mice	Dorota Ferens	502	Cardiovascular
503	Synergistic effect of the combined capsaicin and dihydrocapsaicin on in vitro platelet aggregation	Dominic Geraghty	503	Cardiovascular
504	NTU-D Against Angiotensin-induced Heart Failure	Shih Yi Lee	504	Cardiovascular
505	CCL18 and reactive oxygen species are potential mediators of the pro-fibrotic actions of M2 macrophages	Caitlin Lewis	228	Cardiovascular
506	The β 3-adrenoceptor agonist mirabegron increases human atrial force through β 1- but not β 3-adrenoceptors	Weilan Mo	506	Cardiovascular
507	Plasma cell differentiation is not essential for the pro-hypertensive actions of B cells	Seyuri Moodley	434	Cardiovascular
508	Sex-specific cardiovascular effects of orphan receptor, GPR37L1	Margaret Mouat	508	Cardiovascular
509	α 1A-Adrenoceptors promote glucose uptake and cell growth by activating mTOR	Saori Mukaida	509	Cardiovascular
510	Functional and inflammatory effects of thrombotic cortical stroke in males and females	Catherine Nguyen	430	Cardiovascular
511	Platelet inhibition by inhaled nitrite in healthy volunteers and beta-thalassemia / haemoglobin E patients	Tipparat Parakaw	511	Cardiovascular
512	Effects of platelet-derived growth factor-BB and its association in antiproliferative effect of sera from thalassemia patients on pulmonary artery endothelial cells	Krit Rattanawonsakul	512	Cardiovascular
513	Cavin-1 Deficiency Impairs Myocardial and Coronary Responses to Stretch and Ischemia: Roles of NOS Dysregulation	Melissa Reichelt	513	Cardiovascular
514	Identification of adenosine receptors in rat isolated cardiac fibroblasts and myofibroblasts.	Roselyn Rose'meyer	514	Cardiovascular
515	Interleukin-18 is crucial for the development of renal inflammation and elevated blood pressure in a mouse model of hypertension	Jordyn Thomas	429	Cardiovascular
516	Targeting angiotensin receptors to modulate human fibrosis in vitro	Yan Wang	516	Cardiovascular
517	Non-adrenergic, non-cholinergic (NANC) neurogenic dilatation of rat mesenteric arteries involves opening of potassium channels	Rachel Bagnoux	517	Cardiovascular
518	CCL18 as a mediator of the pro-fibrotic actions of M2 macrophages in the vessel wall during hypertension	Mingyu Zhu	433	Cardiovascular
532	High throughput assay for simultaneous analysis of plasma samples of losartan and its metabolite EXP-3174 using automated robotic solid phase extraction coupled to LC-MS/MS	Santosh Adiraju	532	Clinical Pharmacology
533	Dementia and cognitive impairment risk with proton pump inhibitor therapy - a systematic review	Riley Batchelor	533	Clinical Pharmacology
534	Comparison of enquiries for complementary and alternative medicines with enquiries for conventional medicines at the Medicines Information Service at Christchurch Hospital from 2010 to 2016	Marie-Claire Morahan	534	Clinical Pharmacology
535	Exploring the barriers and facilitators of vancomycin guideline compliance	Joanne Chan	535	Clinical Pharmacology
536	Drug-drug interaction and brand-prescribing alerts in an electronic prescribing and administration (ePA) system	Qian Yi Chuah	536	Clinical Pharmacology
537	An investigation of the drug-drug interaction between fusidic acid and statins, leading to rhabdomyolysis	Courtney De Vries	537	Clinical Pharmacology
538	Ginsenosides: Positive modulators of P2X7 in macrophages	Kshitija Dhuna	538	Clinical Pharmacology
539	Does an intervention by a pharmacist improve long-term adherence to cardiovascular medicines?	Sheila Doggrell	539	Clinical Pharmacology
540	Development of a LCMSMS assay for N-methyl 2 pyrrolidone in plasma	Peter Galettis	540	Clinical Pharmacology
541	The pharmacokinetics and pharmacodynamics of febusostat	Bishoy Kamel	246	Clinical Pharmacology
542	Cannabis and exercise performance	Michael Kennedy	542	Clinical Pharmacology
543	The effect of anticholinergic load over time in community-dwelling elderly Australians	Karen Kerr	543	Clinical Pharmacology
544	Development and validation of the dementia-specific medication review electronic decision support system (D-MEDSS®)	Lisa Kouladjian-O'Donnell	544	Clinical Pharmacology
545	Therapeutic Drug Monitoring (TDM) of Vancomycin	Crystal Li	244	Clinical Pharmacology
546	Audit of Melatonin utilisation in aged care in tertiary and secondary hospitals	P K (Poh Kooi) Loh	546	Clinical Pharmacology
547	Simultaneous quantification of 8 drugs (11 metabolites) commonly taken by older people with polypharmacy	John Mach	547	Clinical Pharmacology
548	Impact of polypharmacy and Drug Burden Index (DBI) on physical function in middle aged mice	John Mach	548	Clinical Pharmacology
549	HPLCMS/MS method for simultaneous determination of ten antibiotics (cefazolin, cefepime, cefotaxime, ceftazidime, ciprofloxacin, flucloxacillin, linezolid, meropenem, piperacillin and tazobactam)	Mirjana Radovanovic	549	Clinical Pharmacology
550	Extraction of Metformin During Haemodiafiltration	Felicity Smith	247	Clinical Pharmacology
551	Impact of Educational Intervention on Surgical Prophylaxis Practices to Contain Antimicrobial Resistance	Harsimrat Waraich	551	Clinical Pharmacology
552	Simultaneous determination of dabigatran, rivaroxaban and apixaban in human plasma by liquid chromatography/tandem mass spectrometry	Mei Zhang	552	Clinical Pharmacology
553	Meropenem stability in 24 hour continuous infusion; a simulation study	Katherine Langan	423	Clinical Pharmacology Trainee
554	The Pharmacokinetics of Fentanyl and its Derivatives in Children – a Comprehensive Review	Victoria Ziesenitz	554	Clinical Pharmacology Trainee
570	The anti-inflammatory activity of Australian Eucalyptus spp. (myrtaceae) with Aboriginal ethnopharmacological significance	Most. Afia Akhtar	570	Drug Discovery
571	Assessment of TRPV4-mediated calcium influx induced by receptor activation in MDA-MB-468 breast cancer cells	Kaela Armitage	571	Drug Discovery
572	Assessment of cytosolic free calcium levels in MDA-MB-231 breast cancer cells undergoing cell death following treatment with ceramide and staurosporine	John Bassett	227	Drug Discovery
573	Molecular mechanisms of action of M5 muscarinic acetylcholine receptor allosteric modulators	Alice Berizzi	573	Drug Discovery

Posterboard number	Paper Title	Presenter	Paper reference	Theme
574	Apocynin Attenuates LPS-Induced Mesangial Cell Damage by Suppressing MCP-1 Expression through the Inhibition of MAPKs	Nirmal Prasad Bhatt	574	Drug Discovery
575	An assessment of the effects of doxorubicin on calcium signalling in MDA-MB-231 breast cancer cells	Alice Hui Li Bong	575	Drug Discovery
576	Molecular Determinants of Amylin Receptor Agonism	Rebekah Bower	239	Drug Discovery
577	Defining the putative binding pocket of the orphan G protein-coupled receptor, GPR37L1	Eric Cheung	577	Drug Discovery
578	The novel fatty acid epoxide analogue CTU activates ER-stress in MDA-MB-231 breast cancer cells	Hassan Chouhair	578	Drug Discovery
579	In vivo assessment of M1 muscarinic acetylcholine allosteric modulators	Christopher KH Choy	579	Drug Discovery
580	Targeting CTR1 to enhance the uptake and cytotoxicity of oxaliplatin in colorectal cancer cells	Haigang Cui	580	Drug Discovery
581	High throughput, quantitative analysis of human osteoclast differentiation and activity	Natalie Diepenhorst	581	Drug Discovery
582	ER-LAR-GECO1 and R-CEPIA1er as tools to measure endoplasmic reticulum calcium in breast cancer cells	Mohamed El Washahy	582	Drug Discovery
583	Comparison of binding and functional effects obtained with a subset of safety-related GPCRs	Benoit Foucaq	583	Drug Discovery
584	Novel irreversible agonists acting at the adenosine A1 receptor	Alisa Glukhova	584	Drug Discovery
585	Understanding sweet taste receptor function through heterologous expression systems	Susan Ireland	585	Drug Discovery
586	NTU-CY Inhibits Inflammatory Response and Improves Cardiac Function during Sepsis	Hui-chun Ku	586	Drug Discovery
587	Measuring binding between p75NTR and BDNF peptide mimetic using the ForteBio BLItz system	Qingqing Lin	587	Drug Discovery
588	Signalling of TRV 130 in μ -opioid receptor and variants	Preeti Manandhar	588	Drug Discovery
589	The potential role of a novel endogenous allosteric modulator of muscarinic acetylcholine receptors	Ee Von Moo	234	Drug Discovery
590	Pickpocketing pharmacological neighbours reveals ligands for orphan receptors	Tony Ngo	233	Drug Discovery
591	Structure-Function Analysis of Orthosteric and Allosteric Ligand Binding at the Adenosine A1 Receptor	Anh TN Nguyen	237	Drug Discovery
592	Comparative genotypic and phenotypic analysis of surrogate monocytic-like cell lines and human peripheral blood monocytes	Darren Riddy	592	Drug Discovery
593	Molecular Pharmacology of Human C3a Receptor Modulators	Ranee Singh	593	Drug Discovery
594	Exploring α 1 adrenoceptor ligand residence time	Sean So	594	Drug Discovery
595	Therapeutic targeting of neurodegenerative disease, using transcriptomics and metabolomics in soleus muscle, compared to spinal cord, in mice overexpressing superoxide dismutase1 (SOD1) G86R	Michael Spedding	595	Drug Discovery
596	Ethanol-oxytocin interactions at homomeric glycine receptors expressed in <i>Xenopus laevis</i> oocytes	Dominique Taylor	240	Drug Discovery
597	Identification of TRPC1 as a modulator of AKT phosphorylation in HCC1569 breast cancer cells	Dane Turner	597	Drug Discovery
598	In-chain heteroatom replacements enhance breast cancer cell killing by novel omega-3 epoxyfatty acid bioisosteres	Balasubrahmanyam Umashankar	598	Drug Discovery
599	Transforming Growth Factor beta-Activated Kinase 1 (TAK1) is a novel target for retinal neovascularisation	Jiang Hui Wang	599	Drug Discovery
600	Reduction of translocator protein (TSPO) A147T discrimination with carbazole acetamide analogues	Eryn Werry	600	Drug Discovery
601	Tacrine is a novel allosteric modulator of the β 2-adrenoceptor	Brendan Wilkins	235	Drug Discovery
602	A nitrostyrene derivative inhibits human platelet aggregation through inhibition of cell surface protein disulfide isomerase	Chin-chung Wu	602	Drug Discovery
619	Regulation of UGTs in Cancer	Robyn Meech	619	Drug Disposition and Response
620	Evaluation of Modafinil as a Perpetrator of Metabolic Drug-Drug Interactions (MODDI-14)	Angela Rowland	620	Drug Disposition and Response
621	The inhibitory effect of natural alkaloid compounds on the substrate uptake mediated by human solute carrier transporters (SLCs)	Tahiatul Shams	621	Drug Disposition and Response
622	Are standard dosing regimens of piperacillin/tazobactam adequate for the management of febrile neutropenia? Answers from population pharmacokinetic modelling and Monte Carlo simulations	Fekade Sime	622	Drug Disposition and Response
623	Assessing the substrate depletion of EGFR kinase inhibitor metabolism	Madelé Van Dyk	623	Drug Disposition and Response
624	Mechanism-based PK/PD Modelling Approach to Optimise Synergistic Combinations against Multidrug-resistant <i>Pseudomonas aeruginosa</i> (Pa) and In-vivo Evaluation in a Murine Thigh Infection Model	Rajbharan Yadav	249	Drug Disposition and Response

Tuesday 29 December, 09:30 - 10:25 and 12:30 - 13:25

Posterboard number	Paper Title	Presenter	Paper reference	Theme
519	Estimation of cytokine production levels in response to panel of mitogens in healthy individuals	Rathimalar Ayakannu	519	Inflammation/respiratory
520	HTR2A mediates 5-HT-induced oedema in the mouse trachea, oesophagus and bladder	Larissa Dill	219	Inflammation/respiratory
521	Generating more relevant cellular models of the airways in asthma	Nithya Fernandopulle	521	Inflammation/respiratory
522	β -hexosaminidase release and regulation in lung cells	Nithya Fernandopulle	522	Inflammation/respiratory
523	Time depended effects of dexamethasone on production and degradation of extracellular matrix in cultured human trabecular meshwork cells	Anna Krasilnikova	523	Inflammation/respiratory
524	Inflammation and altered intrapulmonary airway contraction in mice following short-term cigarette smoke exposure are differentially regulated by RAGE and TLR4	Maggie Lam	524	Inflammation/respiratory
525	Characterising vascular changes in a mouse model of bronchopulmonary dysplasia (BPD)	Emma Lamanna	525	Inflammation/respiratory
526	Proteome profiling reveals phospho-cofilin1 as a candidate mediator of TGF- β 1-induced glucocorticoid resistance	Meina Li	230	Inflammation/respiratory
527	FGD2: A new modulator of mast cell activation	Jeremy Metha	220	Inflammation/respiratory
528	The use of three-dimensional cell culture models in the study of idiopathic pulmonary fibrosis	Asres Mitke	218	Inflammation/respiratory
529	Cortisol inhibits selected actions of inhaled corticosteroids (ICS) in human airway epithelium	Danica Radojicic	226	Inflammation/respiratory
530	Respiratory syncytial virus-induced glucocorticoid insensitivity in bronchial epithelial cells: role of pathogen-associated molecular patterns (PAMPs)	Asmaa Radwan	221	Inflammation/respiratory
531	Hypermutable <i>Pseudomonas aeruginosa</i> related to multi-drug resistance in cystic fibrosis patients with respiratory infections	Vanessa Rees	531	Inflammation/respiratory
555	Medication review in Australian residential aged care facilities: a systematic review	Esa Chen	345	Pharmacoepidemiology
556	N-of-1 trials for assessing the effects of deprescribing medications on short-term clinical outcomes in older adults: a systematic review	Alexander Clough	343	Pharmacoepidemiology
557	London care home medication administration errors: multi-compartment compliance aids and original packaging	Julia Gilmartin	557	Pharmacoepidemiology
558	Changes in cardiovascular medication use in long-term care facilities in Finland.	Natali Jokanovic	558	Pharmacoepidemiology
559	The impact of frailty on the association between polypharmacy and mortality in residential aged care facilities	Mona Kalogianis	559	Pharmacoepidemiology
560	Investigation of Hospital Opioid Prescribing among Opioid Naive Surgical Patients	Luke Kardell	341	Pharmacoepidemiology
561	Socioeconomic position and nonadherence to statin therapy under universal coverage	Maarit Jaana Korhonen	561	Pharmacoepidemiology
562	Negative outcomes associated with accidental and intentional extramedical use of prescription opioids in Australia: a scoping review	Samanta Lalic	562	Pharmacoepidemiology
563	Evaluation of the National Minimum Dataset for neurological conditions in older adults	Sujita Narayan	346	Pharmacoepidemiology
564	Mitigating risk and improving processes of care related to polypharmacy in residential aged care services	Leonie Picton	564	Pharmacoepidemiology
565	Are medications associated with fall-related hospital admissions from residential aged care facilities? A case-control study	Taliesin Ryan-Atwood	565	Pharmacoepidemiology
566	Polypharmacy and medication regimen complexity as risk factors for hospitalisation among residents of aged care facilities: a prospective cohort study	Janet Sluggett	566	Pharmacoepidemiology
567	Simplification of Medications Prescribed to Long term care Residents (SIMPLER): protocol for a cluster randomised controlled trial (RCT)	Janet Sluggett	567	Pharmacoepidemiology
568	How often are medicines charted for pro re nata (PRN) use administered in aged care facilities?	Jacqueline Stasinopoulos	568	Pharmacoepidemiology
569	Do medications and prescribing patterns increase the risk of hospitalisations from aged care facilities? A systematic review	Kate Wang	340	Pharmacoepidemiology
605	Antidepressant-like effects of RS-ketamine, but not R-ketamine, S-ketamine, R-norketamine or S-norketamine in the forced swim test using the BALB/c mouse strain	Javed Alam	605	Neuro- and Behavioural Pharmacology
606	Cannabinoid constituent interactions in an animal neuropathic pain model	Sherelle Casey	606	Neuro- and Behavioural Pharmacology
607	Action of centrally administered glucagon-like peptide-1 (7-36) amide to modulate blood glucose, feeding and induce emesis in <i>Suncus murinus</i>	Sze Wa Chan	607	Neuro- and Behavioural Pharmacology
608	Monoterpenes from <i>Cannabis sativa</i> do not affect human cannabinoid receptor activation of K channels in AtT-20 cells	Mark Connor	608	Neuro- and Behavioural Pharmacology
609	Antidepressants and antipsychotics appear to be overprescribed	Simon Dimmitt	609	Neuro- and Behavioural Pharmacology
610	Do human amnion stem cell-derived exosomes improve stroke outcome?	Andrew Ghaly	223	Neuro- and Behavioural Pharmacology
611	α 3 Nicotinic acetylcholine receptor subunit expression is altered in the hypoglossal nucleus in Sudden Infant Death Syndrome (SIDS)	Tina Hinton	611	Neuro- and Behavioural Pharmacology
612	ASIC1a inhibition preserves tissue and improves function after spinal cord injury (SCI)	Liam Koehn	612	Neuro- and Behavioural Pharmacology
613	The Neurodevelopmental Profile of Dimeric and Monomeric mGluR5: Implications for Novel Therapeutics	Jeremy Lum	613	Neuro- and Behavioural Pharmacology
614	Portable optical fiber temperature probe to measure brain hyperthermia in deep brain structures	Stefan Musolino	614	Neuro- and Behavioural Pharmacology
615	GPR52 – A fine-tuner of striatal signalling in schizophrenia?	Daisy Spark	222	Neuro- and Behavioural Pharmacology
616	GPR88 is a key regulator of striatal function	Greg Stewart	616	Neuro- and Behavioural Pharmacology
617	Sex differences in outcome after permanent focal cerebral ischemia	Sandy Uong	617	Neuro- and Behavioural Pharmacology
618	Roles of cysteinyl leukotriene receptor 1 in glioma cell migration and invasion	Pornpun Vivithanaporn	618	Neuro- and Behavioural Pharmacology
625	Potential role of psoralen in hepatotoxicity	Susan Britza	625	Toxicology

Posterboard number	Paper Title	Presenter	Paper reference	Theme
626	Investigation into the toxicity of a multi-ingredient herbal medicine in vitro	Rachael Farrington	626	Toxicology
627	Combining Adverse Outcome Pathways with multitask machine learning to simultaneously improve in silico rodent carcinogenicity prediction performance and enable mechanistic interpretation	Davy Guan	335	Toxicology
628	Mapping the percutaneous absorption of zinc after topical application of commercial products to human skin using synchrotron X-ray fluorescence microscopy	Amy Holmes	628	Toxicology
629	A pharmacological exploration of the in vitro neurotoxicity of king cobra (<i>Ophiophagus hannah</i>) venom	Tam Huynh	334	Toxicology
630	The effect of different concentrations of oxygen and heart drug (dofetilide) on the heart rate and lactate levels in cultured gestational day (GD 13) rat embryos.	Diana Oakes	630	Toxicology
631	Cardiovascular collapse induced by <i>Echis ocellatus</i> venom: an in vivo and in vitro examination	Rahini Ragavan	631	Toxicology
632	Should CMT patients be waltzing with Lyrica?	Alison Shield	632	Toxicology
633	Deaths from drugs and poisons in Australia, 2013	Ashley Stewart	633	Toxicology
635	Pharmacology teaching and learning in the Doctor of Medicine course at the University of Western Australia	Lynette Fernandes	635	Education
636	Development of an international geriatric pharmacology curriculum for medical schools: systematic review and curriculum mapping	Sarah Hilmer	636	Education
637	Evaluation of student perceptions of practical class resources	Matthew Hortomaris	637	Education
638	ePortfolios and reflective practice for enhancing teamwork and communication skills development in a third year Neuropharmacology course at UNSW Australia	Nicole Jones	638	Education
639	Adverse Drug Reaction (ADR) Reporting and Follow Up in a Hospital Setting - A Patient's Perspective	Mike McDonough	639	Education
640	CYP3A5*3 genotype and ABCB1 haplotype are associated with dose-adjusted trough blood tacrolimus concentrations in kidney transplant recipients	Rong Hu	640	Pharmacogenomics
641	Beta2-adrenoceptor haplotypes associated with asthma susceptibility in a multi-ethnic population	Vijaya L Raj	641	Pharmacogenomics
642	Refereeing the Ribonucleotide Race: G-Quadruplexes, Mitochondria and Chronic Viral Infection	Tim Shaw	642	Pharmacogenomics
643	CYP2C9 and CYP2C19 genotype frequency in Aboriginal and non-Aboriginal Australians using the DMET Plus array: a pilot study	Andrew Somogyi	643	Pharmacogenomics
644	Structure based activity of small molecule pyridine P2X1-purinoceptor antagonists for the development of a non-hormonal male contraceptive via the blockade of sperm transport.	Rujeela Acharya	644	Urogenital and Gastrointestinal
645	The gut hormone INSL5 activates multiple signalling pathways in the human enterocyte cell line NCI-H716	Sheng Yu Ang	231	Urogenital and Gastrointestinal
646	Identification of novel irritant sensing mechanisms in the bladder	Ashlee Caldwell	323	Urogenital and Gastrointestinal
647	Evidence for mu and delta opioid receptor coexpression and functional interactions in the mouse colon	Jesse Di Cello	326	Urogenital and Gastrointestinal
648	Pannexin-1 channels and P2X7 receptors in a human colonic mucosa model of colitis: potential roles in inflammatory bowel disease	Erica Diezmos	229	Urogenital and Gastrointestinal
649	The tachykinin NK2 receptor antagonist, ibodutant, displays gender- and agonist-dependence in the human colon	Stelina Drimousis	327	Urogenital and Gastrointestinal
650	Nav1.8 is required for mechanosensation in hypersensitive colonic afferents and Nav-induced colonic pain in vivo	Andelain Erickson	324	Urogenital and Gastrointestinal
651	Visualising functional AC arrangements of the 5-HT3 receptor	Helen Irving	651	Urogenital and Gastrointestinal
652	Does the non-neuronal cholinergic system play a role in inflammatory bowel disease?	Lu Liu	652	Urogenital and Gastrointestinal
653	Are connexins 43 and 45 ATP release channels in the porcine bladder?	Hafiz Sana-ur-rehman	653	Urogenital and Gastrointestinal
654	Biological effects on rat prostatic smooth muscle and chemical fractionation of <i>Costus speciosus</i> rhizome	Nguok Ngie Su	654	Urogenital and Gastrointestinal
655	Evaluation of Active efflux protein expression in gastrointestinal cell lines using chemically defined media	Aparna Warriar	655	Urogenital and Gastrointestinal

Tuesday 29 December, 17:00 - 18:00 and Wednesday 30 December, 09:30 - 10:25 and 12:30 - 13:25

Posterboard number	Paper Title	Presenter	Paper reference	Theme
656	GPCRs effect on human alveolar basal epithelial carcinoma cells (A549)	Sefaa Al-aryahi	656	Molecular Pharmacology of GPCRs (MPGPCR)
657	Investigation of G-Protein-Coupled Receptor-Receptor Tyrosine Kinase heteroreceptor complexes using Bioluminescence Resonance Energy Transfer (BRET)	Diana Alcobia	657	Molecular Pharmacology of GPCRs (MPGPCR)
658	VCP746, a biased adenosine A1/A2B receptor agonist, promotes divergent cardioprotective signalling from that of NECA, a prototypical adenosine receptor agonist	Jo-Anne Baltos	302	Molecular Pharmacology of GPCRs (MPGPCR)
659	Glucagon receptor intracellular loop 1; a role Gαq/11-mediated intracellular calcium release	Kerry Barkan	659	Molecular Pharmacology of GPCRs (MPGPCR)
660	An investigation into biased signalling at the glucagon receptor	Kerry Barkan	660	Molecular Pharmacology of GPCRs (MPGPCR)
661	Small molecule positive modulators of a class B GPCR, the adrenomedullin 1 receptor	Erica Burns	661	Molecular Pharmacology of GPCRs (MPGPCR)
662	Dissecting the bias and binding properties of chemically distinct Glucagon-like peptide-1 receptor agonists	Lachlan Clydesdale	662	Molecular Pharmacology of GPCRs (MPGPCR)
663	Teaching old receptors new tricks: computational method to generate new GPCR/ligand complexes	Thomas Coudrat	663	Molecular Pharmacology of GPCRs (MPGPCR)
664	Characterisation of signalling and regulation of common calcitonin receptor splice variants and polymorphisms	Emma Dal Maso	664	Molecular Pharmacology of GPCRs (MPGPCR)
665	Protease activated receptor-2 signals to and opens transient receptor potential vanilloid-4 via Gα13 and p38δ	William Darby	665	Molecular Pharmacology of GPCRs (MPGPCR)
666	Divergent effects of strontium and calcium-sensing receptor positive modulators on osteoclast activity	Natalie Diepenhorst	666	Molecular Pharmacology of GPCRs (MPGPCR)
667	Dynamic ligand binding underlies the mechanism of action of a novel class of allosteric modulator of the dopamine D2 receptor	Christopher Draper-Joyce	667	Molecular Pharmacology of GPCRs (MPGPCR)
668	Roles of the intraloops and C-terminus in calcium/calcimimetic selection of G-protein dependant signalling pathways from the calcium-sensing receptor	Kimberly Edwards	668	Molecular Pharmacology of GPCRs (MPGPCR)
669	Off-target effects contribute to apparent agonist bias at human α1A-adrenoceptors	Bronwyn Evans	669	Molecular Pharmacology of GPCRs (MPGPCR)
670	An essential role of RGS protein in partial agonism of the m2 muscarinic receptor-mediated K+ currents	Kazuharu Furutani	670	Molecular Pharmacology of GPCRs (MPGPCR)
671	Targeting meta-stable binding sites with bitopic ligands – a new concept in GPCR medicinal chemistry	Birgit Isabel Gaiser	671	Molecular Pharmacology of GPCRs (MPGPCR)
672	Probing the functional importance of the linker region of the class B GPCR, CLR, in CGRP and adrenomedullin receptors.	Michael Garelja	672	Molecular Pharmacology of GPCRs (MPGPCR)
673	Insights into the allosteric binding sites of the M5 muscarinic acetylcholine receptor	Patrick Gentry	673	Molecular Pharmacology of GPCRs (MPGPCR)
674	Characterising signalling bias of Glucose-dependent Insulinotropic Polypeptide receptor ligands	Matthew Harris	674	Molecular Pharmacology of GPCRs (MPGPCR)
675	Allosteric modulators of mGlu5 desensitise multiple signalling pathways in striatal neurons	Shane Hellyer	675	Molecular Pharmacology of GPCRs (MPGPCR)
676	The inner workings of a GPCR: Molecular basis for biased G protein activation and beta-arrestin recruitment	Franziska Heydenreich	305	Molecular Pharmacology of GPCRs (MPGPCR)
677	Identifying small molecule agonists of glucagon-like peptide-1 receptor	Caroline Hick	677	Molecular Pharmacology of GPCRs (MPGPCR)
678	Development of a Nanoluc BRET binding assay for investigating the complex relaxin-RXFP1 interaction	Bradley Hoare	678	Molecular Pharmacology of GPCRs (MPGPCR)
679	Structural insights into differential agonism by MCP-1 and MCP-3 at their shared receptor CCR2	Zil E Huma	679	Molecular Pharmacology of GPCRs (MPGPCR)
680	Heteromerisation of the angiotensin II type 2 receptor and the bradykinin type 2 receptor	Elizabeth Johnstone	680	Molecular Pharmacology of GPCRs (MPGPCR)
681	G protein coupled receptor mediated Smad2 linker region phosphorylation in cardiovascular disease	Danielle Kamato	681	Molecular Pharmacology of GPCRs (MPGPCR)
682	It's only a matter of time: Investigating the temporal aspects of dopamine D2 receptor signalling	Alastair Keen	682	Molecular Pharmacology of GPCRs (MPGPCR)
683	Discovery of a vasopressin V1a receptor-selective antagonist through D-amino acid substitution of the insect peptide inotocin	Peter Keov	683	Molecular Pharmacology of GPCRs (MPGPCR)
684	Probing the binding site(s) of calcium sensing receptor (CaSR) negative allosteric modulators (NAMs)	Elham Khajehali	684	Molecular Pharmacology of GPCRs (MPGPCR)
685	Endosomal Signalling and Trafficking of the Calcitonin Gene-Related Peptide Receptor in Pain	Carmen Klein Herenbrink	685	Molecular Pharmacology of GPCRs (MPGPCR)
686	ML290 is a small molecule biased agonist at relaxin family peptide receptor 1 (RXFP1)	Martina Kocan	686	Molecular Pharmacology of GPCRs (MPGPCR)
687	Tendency of class B G protein-coupled secretin and GLP-1 receptors to self-associate and cross-associate when co-expressed on the same cell	Shannen Lau	687	Molecular Pharmacology of GPCRs (MPGPCR)
688	Context-dependent allosteric modulation of the human calcium sensing receptor (CaSR). Implications for drug discovery.	Katie Leach	688	Molecular Pharmacology of GPCRs (MPGPCR)
689	The TM1/N-terminal domain interface of the GLP-1R is crucial for agonist affinity and biased agonism	Saifei Lei	689	Molecular Pharmacology of GPCRs (MPGPCR)
690	Purification of active human Calcitonin receptor and Gs heterotrimer complex	Yi-Lynn Liang	690	Molecular Pharmacology of GPCRs (MPGPCR)
691	A novel PAM that selectively boosts the action of agonists at the dopamine D2 receptor	Herman Lim	691	Molecular Pharmacology of GPCRs (MPGPCR)
692	Agonist-mediated regulation of the striatal orphan receptor, GPR52	Yao (jackie) Lu	692	Molecular Pharmacology of GPCRs (MPGPCR)
693	Extracellular loop 2 of the GLP-1R is a crucial domain for controlling agonist affinity and biased agonism	Jordan Michaelis	693	Molecular Pharmacology of GPCRs (MPGPCR)
694	Use of BRET to demonstrate AT1R-EGFR complexes and AT1R-mediated EGFR transactivation	Shannon O'Brien	694	Molecular Pharmacology of GPCRs (MPGPCR)
695	Expression and signalling of calcitonin family receptors in four patient-derived GBM cell lines	Anna Ostrovskaya	695	Molecular Pharmacology of GPCRs (MPGPCR)

Posterboard number	Paper Title	Presenter	Paper reference	Theme
696	High Affinity α 1B-adrenoceptor or Low Affinity β 2-adrenoceptor Resting States Stabilised by Disrupting the Hydrogen Bond Network between the NPxxY Motif and TMH5	Lotten Ragnarsson	696	Molecular Pharmacology of GPCRs (MPGPCR)
697	Characterising the signalling of amylin receptors	Tayla Rees	697	Molecular Pharmacology of GPCRs (MPGPCR)
698	The use of Fluorescence Correlation Spectroscopy to investigate ligand-receptor interaction at the Neuropeptide Y Y1 receptor	Rachel Richardson	698	Molecular Pharmacology of GPCRs (MPGPCR)
699	Isoform-specific bias of histamine H3 receptor agonists	Darren Riddy	699	Molecular Pharmacology of GPCRs (MPGPCR)
700	GLP-2R signalling is modulated by RAMPs	Sarah Routledge	700	Molecular Pharmacology of GPCRs (MPGPCR)
701	Desensitization of CB1 receptor signaling by valinate and tert-leucinate synthetic cannabinoids.	Shivani Sachdev	701	Molecular Pharmacology of GPCRs (MPGPCR)
702	Biased agonism at the CC chemokine receptor CCR1	Julie Sanchez	702	Molecular Pharmacology of GPCRs (MPGPCR)
703	Novel allosteric modulators of M1 muscarinic acetylcholine receptors	Arthur Spathis	703	Molecular Pharmacology of GPCRs (MPGPCR)
704	Arrestin biased GPCR agonism induces acute catecholamine secretion through TRPC3 coupling	Jinpeng Sun	704	Molecular Pharmacology of GPCRs (MPGPCR)
705	mTOR has a key role in α 1-adrenoceptors mediated cardioprotection in hypoxic neonatal rat cardiomyocytes	Bui San Thai	705	Molecular Pharmacology of GPCRs (MPGPCR)
706	Probing ligand binding modes and allostereism at ultra-stable α 1-adrenergic receptors with NMR	Tasneem Vaid	706	Molecular Pharmacology of GPCRs (MPGPCR)
707	Investigating relaxin family peptide receptor 1 (RXFP1) signalling using a novel cAMP signalling biosensor	Adam Valkovic	707	Molecular Pharmacology of GPCRs (MPGPCR)
708	Identification of a potent adenosine A2B receptor agonist that stimulates cardiac anti-fibrotic signalling	Elizabeth Vecchio	708	Molecular Pharmacology of GPCRs (MPGPCR)
709	Development of fluorescent ligands as tools for studying cannabinoid type 2 receptor	Andrea Vernall	709	Molecular Pharmacology of GPCRs (MPGPCR)
710	The effects of cannabinoid ligands on the gene expression profile in murine adipocytes	Teresa Vu	710	Molecular Pharmacology of GPCRs (MPGPCR)
711	Using BRET-based Rluc8-EKAR-Venus pERK1/2 biosensors to characterise RXFP1 signalling	Alice Whitehead	711	Molecular Pharmacology of GPCRs (MPGPCR)
712	Quantifying biased agonism of novel, adenosine and NECA-based, adenosine A1 receptor agonists	Ian Winfield	712	Molecular Pharmacology of GPCRs (MPGPCR)
713	Identifying novel triazoloquinazolines as dual target A2AR/PDE10A compounds, with a potential therapeutic application in Huntingdon disease	Ian Winfield	713	Molecular Pharmacology of GPCRs (MPGPCR)
714	Intracellular loop 1 of family B GPCRs determines G protein specificity	Ian Winfield	714	Molecular Pharmacology of GPCRs (MPGPCR)
715	Understanding agonist and antagonist interactions at the relaxin-3 receptor, RXFP3	Lilian Wong	715	Molecular Pharmacology of GPCRs (MPGPCR)
716	Characterisation of the internalisation and compartmentalised signalling of the GLP-1R	Denise Wootten	716	Molecular Pharmacology of GPCRs (MPGPCR)
717	Role of conformational dynamics on the functional selectivity of α 1-adrenoceptor.	Feng-Jie Wu	717	Molecular Pharmacology of GPCRs (MPGPCR)
718	Structural determinants of binding the seven-transmembrane domain of the glucagon-like peptide-1 receptor	Dehua Yang	718	Molecular Pharmacology of GPCRs (MPGPCR)
719	Mechanisms involved in PKC mediated regulation of μ opioid receptor desensitization.	Arsalan Yousuf	719	Molecular Pharmacology of GPCRs (MPGPCR)
720	Analysis of the C-terminus of the human amylin peptide to inform the development of new treatments for diabetes and obesity	Lauren Yule	720	Molecular Pharmacology of GPCRs (MPGPCR)
721	Regulation of Compartmentalized Protease-Activated Receptor-2 Signaling by Receptor Trafficking	Peishen Zhao	721	Molecular Pharmacology of GPCRs (MPGPCR)